Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
DUBLIN, Ireland, May 05, 2023 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq:TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, today reported the receipt of a formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Listing Rule 5450(a)(1), which requires the Company’s ordinary shares to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this determination of compliance after the closing bid price of the Company’s ordinary shares was at $1.00 per share or greater for the prior 10 consecutive business days. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1) and Nasdaq considers the prior bid price deficiency matter now closed.
Related news for (TRIB)
- Powering Into the Close: Biotech and Blockchain Light Up Late Session
- Midday Movers: Biotech Gets Bold- From Fentanyl Defense to Tokenized Stem Cells
- Don’t Miss Out: MoBot’s Latest Stock Updates 08/20/25 09:00 AM
- Gene Therapy, Global Patents & Cancer Innovation: Biopharma Heats Up as Trials Restart and Tech Advances
- Today’s Top Performers: MoBot’s Market Review 08/14/25 10:00 AM